Intranasal application of dopamine reduces activity and improves attention in Naples High Excitability rats that feature the mesocortical variant of ADHD

European Neuropsychopharmacology

Volumn 19, Issue 10, 2009, Pages 693-701

  Ruocco, Lucia A ^a   de Souza Silva, Maria A ^b   Topic, Bianca ^b   Mattern, Claudia ^c   Huston, Joseph P ^b   Sadile, Adolfo G ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c M et P Pharma AG   (Switzerland)

Author keywords

ADHD; Attention; Dopamine; Hyperactivity; Intranasal route; L t maze; NHE rats; Olton maze

Indexed keywords

DOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION DEFICIT DISORDER; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG DOSE COMPARISON; JUVENILE ANIMAL; LOCOMOTION; MALE; MAZE TEST; MOTOR ACTIVITY; NAPLES HIGH EXCITABILITY RAT; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; SELECTIVE ATTENTION;

ADMINISTRATION, INTRANASAL; ANIMALS; ATTENTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DISEASE MODELS, ANIMAL; DOPAMINE; HYPERKINESIS; MALE; MAZE LEARNING; MOTOR ACTIVITY; RANDOM ALLOCATION; RATS; RATS, INBRED STRAINS;

EID: 69049086579     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2009.02.005     Document Type: Article

References (57)

1. Advokat C. Update on amphetamine neurotoxicity and its relevance to the treatment of ADHD. J. Atten. Disord. 11 (2007) 8-16
2. Arnsten A.F. Stimulants: therapeutic actions in ADHD. Neuropsychopharmacology 31 (2006) 2376-2383
3. Aspide R., Gironi Carnevale U.A., Sergeant J.A., and Sadile A.G. Non-selective attention and nitric oxide in putative animal models of Attention-Deficit Hyperactivity Disorder. Behav. Brain Res. 95 (1998) 123-133
4. Aspide R., Fresiello A., De Filippis G., Gironi Carnevale U.A., and Sadile A.G. Non-selective attention in a rat model of hyperactivity and attention deficit: subchronic methylphenidate and nitric oxide synthesis inhibition treatment. Neurosci. Biobehav. Rev. 24 (2000) 59-72
5. Biederman J., and Faraone S.V. Attention-deficit hyperactivity disorder. Lancet 366 (2005) 237-248
6. Bonina F., Puglia C., Rimoli M.G., Melisi D., Boatto G., Nieddu M., Calignano A., La Rana G., and De Caprariis P. Glycosyl derivatives of dopamine and L-dopa as anti-Parkinson prodrugs: synthesis, pharmacological activity and in vitro stability studies. J. Drug Target. 11 (2003) 25-36
7. Brennan A.R., and Arnsten A.F. Neuronal mechanisms underlying attention deficit hyperactivity disorder: the influence of arousal on prefrontal cortical function. Ann. N.Y. Acad. Sci. 1129 (2008) 236-245
8. Broadhurst P.L. Experiments in psychogenetics: application of biometrical genetics to the inheritance of behavior. In: Eysenk H.J. (Ed). Experiments in Personality. Psychogenetics and Psychopharmacology vol. I (1960), Routledge, Regan Paul, London 1-102
9. Buddenberg T.E., Topic B., Mahlberg E.D., de Souza Silva M.A., Huston J.P., and Mattern C. Behavioral actions of intranasal application of dopamine: effects on forced swimming, elevated plus-maze and open field parameters. Neuropsychobiology 57 (2008) 70-79
10. Bymaster F.P., Katner J.S., Nelson D.L., Hemrick-Luecke S.K., Threlkeld P.G., Heiligenstein J.H., Morin S.M., Gehlert D.R., and Perry K.W. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27 (2002) 699-711
11. Cerbone A., Pellicano M.P., and Sadile A.G. Evidence for and against the Naples high- and low-excitability rats as genetic model to study hippocampal functions. Neurosci. Biobehav. Rev. 17 (1993) 295-303
12. Chemuturi N.V., Haraldsson J.E., Prisinzano T., and Donovan M. Role of dopamine transporter (DAT) in dopamine transport across the nasal mucosa. Life Sci. 79 (2006) 1391-1398
13. Chen N., and Reith M.E. Structure and function of the dopamine transporter. Eur.J. Pharmacol. 405 (2000) 329-339
14. Dahlin M., Bergman U., Jansson B., Bjork E., and Brittebo E. Transfer of dopamine in the olfactory pathway following nasal administration in mice. Pharm. Res. 17 (2000) 737-742
15. Dahlin M., Jansson B., and Bjork E. Levels of dopamine in blood and brain following nasal administration to rats. Eur. J. Pharm. Sci. 14 (2001) 75-80
16. Dalpiaz A., Filosa R., De Caprariis P., Conte G., Bortolotti F., Biondi C., Scatturin A., Prasad P.D., and Pavan B. Molecular mechanism involved in the transport of a prodrug dopamine glycosyl conjugate. Int. J. Pharm. 336 (2007) 133-139
17. Davids E., Zhang K., Tarazi F.I., and Baldessarini R.J. Animal models of attention-deficit hyperactivity disorder. Brain. Res. Brain. Res. Rev. 42 (2003) 1-21
18. de Souza Silva M.A., Mattern C., Hacker R., Nogueira P.J., Huston J.P., and Schwarting R.K. Intranasal administration of the dopaminergic agonists L-DOPA, amphetamine, and cocaine increases dopamine activity in the neostriatum: a microdialysis study in the rat. J. Neurochem. 68 (1997) 233-239
19. de Souza Silva M.A., Mattern C., Hacker R., Tomaz C., Huston J.P., and Schwarting R.K. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment. Synapse 27 (1997) 294-302
20. de Souza Silva M.A., Topic B., Huston J.P., and Mattern C. Intranasal dopamine application increases dopaminergic activity in the neostriatum and nucleus accumbens and enhances motor activity in the open field. Synapse 62 (2008) 176-184
21. Faber W.M. The nasal mucosa and the subarachnoid space. Am. J. Anat. 62 (1938) 121-148
22. Gentsch C., Lichtsteiner M., and Feer H. Locomotor activity, defecation score and corticosterone levels during an openfield exposure: a comparison among individually and group-housed rats, and genetically selected rat lines. Physiol. Behav. 27 (1981) 183-186
23. Gironi Carnevale U.A., Vitullo E., and Sadile A.G. Post-trial NMDA receptor allosteric blockade differentially influences habituation of behavioral responses to novelty in the rat. Behav. Brain Res. 39 (1990) 187-195
24. Gironi Carnevale U.A., Vitullo E., Varriale B., Ruocco L.A., and Sadile A.G. A classical Mendelian cross-breeding study of the Naples high and low excitability rat lines. Behav. Brain Res. 183 (2007) 130-140
25. Graff C.L., and Pollack G.M. Nasal drug administration: potential for targeted central nervous system delivery. J. Pharm. Sci. 94 (2005) 1187-1195
26. Heijtz R.D., Kolb B., and Forssberg H. Motor inhibitory role of dopamine D1 receptors: implications for ADHD. Physiol. Behav. 92 (2007) 155-160
27. Horst R.O., and Hendren R.L. Integrated pharmacologic treatment of attention-deficit hyperactivity disorder (ADHD). Essent. Psychopharmacol. 6 (2005) 250-261
28. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur. J. Pharm. Sci. 11 (2000) 1-18
29. Illum L. Is nose-to-brain transport of drugs in man a reality?. J. Pharm. Pharmacol. 56 (2004) 3-17
30. Illum L. Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems?. J. Pharm. Sci. 96 (2007) 473-483
31. Krause J. SPECT and PET of the dopamine transporter in attention-deficit/hyperactivity disorder. Expert Rev. Neurother. 8 (2008) 611-625
32. Madaan V., Kinnan S., Daughton J., and Kratochvil C.J. Innovations and recent trends in the treatment of ADHD. Expert Rev. Neurother. 6 (2006) 1375-1385
33. Mehler-Wex C., Riederer P., and Gerlach M. Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder. Neurotox. Res. 10 (2006) 167-179
34. Oades R.D., Sadile A.G., Sagvolden T., et al. The control of responsiveness in ADHD by catecholamines: evidence for dopaminergic, noradrenergic and interactive roles. Dev. Sci. 8 (2005) 122-131
35. Reis H.J., Rosa D.V., Guimaraes M.M., Souza B.R., Barros A.G., Pimenta F.J., Souza R.P., Torres K.C., and Romano-Silva M.A. Is DARPP-32 a potential therapeutic target?. Expert Opin. Ther. Targets 11 12 (2007) 1649-1661
36. Revay R., Vaughan R., Grant S., and Kuhar M.J. Dopamine transporter immunohistochemistry in median eminence, amygdala, and other areas of the rat brain. Synapse 22 (1996) 93-99
37. Ruocco L.A., Viggiano D., Viggiano A., et al. Galactosylated dopamine enters into the brain, blocks the mesocorticolimbic system and modulates activity and scanning time in Naples high excitability rats. Neuroscience 152 (2008) 234-244
38. Ruocco L.A., Viggiano D., Pignatelli M., Iannaccone T., Rimoli M.G., Melisi D., Curcio A., De Lucia S., Carboni E., Carnevale U.A., de Caprariis P., and Sadile A.G. Galactosilated dopamine increases attention without reducing activity in C57BL/6 mice. Behav. Brain Res. 187 (2008) 449-454
39. Sadile A.G. Long-term habituation of theta-related activity components of albino rats in the Làt-maze. In: Sanberg P.R., Ossenkopp K.P., and Kavaliers M. (Eds). Motor Activity and Movement Disorders: Measurement and Analysis (1996), Humana Press, New York 1-54
40. Sadile A.G., Gironi Carnevale U.A., Vitullo E., Cioffi L.A., Welzl H., and Bättig K. Maze learning of the Naples high- and low-excitability rat lines. Adv. Biosci. 70 (1988) 177-180
41. Sagvolden T. Behavioral validation of the spontaneously hypertensive rat (SHR) as an animal model of attention-deficit/hyperactivity disorder (AD/HD). Neurosci. Biobehav. Rev. 24 (2000) 31-39
42. Sanders D.C. The Bethlem lines: genetic selection for high and low rearing activity in rats. Behav. Genet. 11 (1981) 491-503
43. Sergeant J.A., Geurts H., Huijbregts S., Scheres A., and Oosterlaan J. The top and the bottom of ADHD: a neuropsychological perspective. Neurosci. Biobehav. Rev. 27 (2003) 583-592
44. Sikstrom S., and Soderlund G. Stimulus-dependent dopamine release in attention-deficit/hyperactivity disorder. Psychol. Rev. 114 (2007) 1047-1075
45. Solanto M.V. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav. Brain Res. 94 (1998) 127-152
46. Sonuga-Barke E.J. The dual pathway model of AD/HD: an elaboration of neuro-developmental characteristics. Neurosci. Biobehav. Rev. 27 (2003) 593-604
47. Swanson J.M., Sergeant J.A., Taylor E., Sonuga-Barke E.J., Jensen P.S., and Cantwell D.P. Attention-deficit hyperactivity disorder and hyperkinetic disorder. Lancet 351 (1998) 429-433
48. Swanson J.M., Kinsbourne M., Nigg J., et al. Etiologic subtypes of attention-deficit/hyperactivity disorder: brain imaging, molecular genetic and environmental factors and the dopamine hypothesis. Neuropsychol. Rev. 17 (2007) 39-59
49. Thorne R.G., and Frey W.H. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin. Pharmacokinet. 40 (2001) 907-946
50. van Abeelen J.H. Genetics of rearing behavior in mice. Behav. Genet. 1 (1970) 71-76
51. Vanderwolf C.H. Hippocampal electrical activity and voluntary movement in the rat. Electroencephalogr. Clin. Neurophysiol. 26 (1969) 407-418
52. Vanderwolf C.H. Suppression of serotonin-dependent cerebral activation: a possible mechanism of action of some psychotomimetic drugs. Brain Res. 414 (1987) 109-118
53. Viggiano D., Vallone D., Welzl H., and Sadile A.G. The Naples High- and Low-Excitability rats: selective breeding, behavioral profile, morphometry, and molecular biology of the mesocortical dopamine system. Behav. Genet. 32 (2002) 315-333
54. Viggiano D., Ruocco L.A., and Sadile A.G. Dopamine phenotype and behaviour in animal models: in relation to attention deficit hyperactivity disorder. Neurosci. Biobehav. Rev. 27 7 (2003) 623-637
55. Viggiano D., Vallone D., Ruocco L.A., and Sadile A.G. Behavioural, pharmacological, morpho-functional molecular studies reveal a hyperfunctioning mesocortical dopamine system in an animal model of attention deficit and hyperactivity disorder. Neurosci. Biobehav. Rev. 27 (2003) 683-689
56. Viggiano D., Ruocco L.A., Arcieri S., and Sadile A.G. Involvement of norepinephrine in the control of activity and attentive processes in animal models of attention deficit hyperactivity disorder. Neural Plast. 11 (2004) 133-149
57. Weisler R.H. Safety, efficacy and extended duration of action of mixed amphetamine salts extended-release capsules for the treatment of ADHD. Expert Opin. Pharmacother. 6 (2005) 1003-1018